What RVX hopes happens in the Covid trial has no relevance to negotiations for ZEN-3694 and the different diseases Zenith is demonstrating safety and efficacy for.  Does anybody really think that because RVX hopes for a good Covid trial, Newsoara would pay more for a license for Zenith's ZEN-3694?

Anyhow, I don't see a problem with today's news.  No one even knows what the milesone and royalty payments will be but are critical.